Key result
The coronary sinus Reducer was associated with higher quality-adjusted life years compared to standard of care, demonstrating cost-effectiveness across multiple countries.
Why the study?
The coronary sinus Reducer improves symptoms in refractory angina, but its potential cost-effectiveness and impact on healthcare resource use required evaluation.
Is the coronary sinus Reducer cost-effective compared to standard of care in patients with refractory angina?
Observational (n=215)
Yes
Is the coronary sinus Reducer cost-effective compared to standard of care in patients with refractory angina?
The coronary sinus Reducer is a cost-effective intervention that reduces healthcare resource utilization and improves quality-adjusted life years in patients with refractory angina.
Answers are grounded in this paper and cite their sources.
May support cost-effective Reducer option in refractory angina; leaves open randomized confirmation.
AIMS: The coronary sinus Reducer is a percutaneous device proven to improve angina symptoms in refractory angina (RA). We evaluated its potential cost-effectiveness and impact on the healthcare resource use. METHODS AND RESULTS: Angina-related healthcare resource usage and quality-of-life data were collected for 215 consecutive RA patients undergoing Reducer implantation in Belgium, the Netherlands, and Italy. Costs were assessed from each country's healthcare system perspective. Data from the date of RA diagnosis to Reducer implantation [Standard-of-Care (SoC)-period] and from Reducer implantation to follow-up (Reducer-period) were compared: during Reducer-period, a significant reduction in angina-driven hospitalizations, outpatient visits, coronary angiograms, and percutaneous coronary interventions per patient-year was observed, translating into significantly reduced costs per patient-year. To assess cost-effectiveness, costs and utilities of 1-year SoC were compared with those of 1-year Reducer-period. Assumptions on Reducer efficacy duration were further explored with modelled projections. Reducer was associated with higher quality-adjusted life years (QALYs: 0.665 vs. 0.580, P < 0.001) and incremental costs, yielding incremental cost-effectiveness ratios (ICERs) of 53 197, 34 948, 63 146 €/QALY gained in Belgium, the Netherlands, and Italy, respectively. Under both the assumptions of 2 and 3 years Reducer effect duration with a 30%-year efficacy decrease, the device yielded ICERs in the range of 1977-20 796 €/QALY gained. CONCLUSION: In patients with RA, Reducer device decreases healthcare resource use and related costs. In a limited 1-year timeframe, Reducer is consistently cost-effective according to a range of cost-effectiveness thresholds. Under the explored assumptions, the device yields cost-effectiveness ratios suggesting high value from all the considered perspectives.
No takes yet. Share an insight, caveat, or question.
Gallone et al. (2019) conducted an observational in refractory angina (n=215). Coronary sinus Reducer vs. Standard-of-Care (SoC)-period was evaluated on Quality-adjusted life years (QALYs) (p=<0.001). The coronary sinus Reducer was associated with higher quality-adjusted life years compared to standard of care, demonstrating cost-effectiveness across multiple countries.
Synapse has enriched 10 related papers. Consider them for comparative context: